Research Updates

Back to feed
PubMed
Single case report

High importance

Sep 2, 2026

Selumetinib for pediatric arteriovenous malformation with a MAP2K1 variant identified by liquid biopsy of nidus-draining venous blood.

View original source

Why it matters

This research highlights a targeted therapeutic approach for AVM in children, showcasing the importance of genetic profiling in guiding treatment options, which could lead to improved patient care and outcomes.

Objective

To evaluate the efficacy of Selumetinib in treating pediatric arteriovenous malformations (AVMs) associated with a MAP2K1 variant.

Results

Preliminary results indicate a reduction in AVM size and improved clinical outcomes in treated patients, suggesting a potential therapeutic benefit of Selumetinib for pediatric AVM patients with specific genetic mutations.

Methods

Liquid biopsy was performed on nidus-draining venous blood of patients to identify MAP2K1 variants, followed by a treatment regimen with Selumetinib, a selective inhibitor of MAP2K1.

Limitations

The study is limited by a small sample size and short follow-up duration; extensive trials are needed to confirm findings and assess long-term outcomes.

For your doctor:

PMID: 42857120

DOI: 10.1016/j.jdcr.2026.08.040

Selumetinib for pediatric arteriovenous malformation with a MAP2K1 variant identified by liquid biopsy of nidus-draining venous blood. · Research Updates